Quest Diagnostics Incorporated
- 取引所
- 米国株
- 国 / 地域
- USA
- 上場日
- 1996年12月17日
- 従業員数
- 57,000
総合バリュエーションレンジ · 保守的 $135–$155 / 妥当 $180–$205 / 楽観的 $230–$255。$231.84 時点で 楽観的な本源的価値レンジ内 · 多くの期待を織り込み済み。
レポート公開時 $196.2（2026年5月29日）
データ提供：EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
沿革
Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey. The company went public on December 17, 1996. It operates a nationwide diagnostic information services network, offering routine, non-routine, and advanced clinical testing, anatomic pathology, and related services under the Quest Diagnostics brand as well as the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands. The company has expanded substantially through acquisitions, completing a series of deals in 2024 including LifeLabs, Allina, OhioHealth, University Hospitals, and three New York physician group laboratories. As of 2025 it processed roughly 244 million test requisitions across about 8,000 patient access points, including approximately 2,400 patient service centers, and employs around 57,000 people.
業界での地位
Quest Diagnostics is one of the two dominant players in the U.S. independent clinical laboratory market, together with Labcorp forming a duopoly. According to its 2025 Investor Day, the U.S. laboratory market is about $89 billion, split between a physician channel of roughly $58 billion and a hospital channel of roughly $31 billion. Diagnostic Information Services accounted for more than 95% of the company's revenue through the first quarter of 2026. Its competitive advantages stem from scale rather than a single brand or patent: a nationwide laboratory network, logistics density, broad patient access reaching more than 90% of U.S. insured lives, deep IT and interface integration with clinical workflows, and the operating data accumulated from processing about 244 million requisitions, which the company describes as one of the largest de-identified clinical laboratory databases globally. These factors create switching costs through ordering interfaces, EHR connectivity, phlebotomy coverage, and existing contracts. The company itself characterizes the industry as fragmented and highly competitive in its 10-K, with its principal competitor Labcorp generating $13.95 billion in 2025 revenue, of which Diagnostics Laboratories represented about 78%; the broader field also includes numerous regional independent laboratories, hospital outreach laboratories, and physician office labs.
この銘柄のレポートはお使いの言語でまだありません。